U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive

BioMarin shares fell 31%, or $37, to $81.54 in morning trading. There are about 16,000 patients in the United States with hemophilia A in which they are missing the factor VIII clotting protein. It was hoped the gene therapy would enable patients to forego or reduce those infusions. …read more

Source:: Yahoo Finance